Page 101 - 《中国药房》2021年第4期
P. 101

·药物与临床·

        山东省8 566例新的药品不良反应报告分析                                             Δ


        刘宝生 ,周秀丽 ,宫凯凯(1.潍坊市中医院临床药学科,山东 潍坊 261000;2.阳光融和医院药学部,山东 潍
                                 3
                        2 #
              1*
        坊 261000;3.滨州医学院附属医院肿瘤研究实验室,山东 滨州 256603)
        中图分类号 R969.3         文献标志码 A           文章编号 1001-0408(2021)04-0475-05
        DOI  10.6039/j.issn.1001-0408.2021.04.14

        摘  要   目的:了解山东省新的药品不良反应(ADR)发生的现状及特点,为保障患者用药安全提供参考。方法:调取2019年10
        月-2020年3月上报至山东省ADR监测中心自发呈报系统新的ADR报告的相关数据,对报告类型、上报机构、报告人职业和患者
        性别、年龄、药物类型、累及器官/系统、临床表现等情况进行统计分析。结果与结论:共筛选出新的 ADR 报告 8 566 例,占有效
        ADR的10.81%;其中新的一般的ADR有7 961例(占92.94%),新的严重的ADR有605例(占7.06%)。新的ADR中,上报机构以
        医疗机构(占 98.42%)为主,报告人职业以医师(占 78.44%)为主;女性(4 860 例)略多于男性(3 698 例),45 岁及以上人群(占
        70.00%)居多;静脉滴注(占47.67%)为主要给药途径。新的ADR怀疑药品排名前5位的药品类别依次为中药制剂(34.50%)、抗
        微生物药物(13.75%)、循环系统用药(11.41%)、神经系统用药(6.39%)、血液系统药物(4.81%),分别涉及517、91、64、53、50个品
        种,其中左氧氟沙星注射液致新的严重的ADR数量最多(24例)。新的一般的ADR主要累及胃肠系统、皮肤及其附件,临床表现
        为恶心、呕吐、皮疹等;新的严重的ADR主要造成全身性损害,临床表现为过敏性休克、胸闷、寒战等。建议临床加强对中药制剂、
        抗微生物药物、循环系统用药等药物的ADR监测,保障患者临床用药安全。
        关键词 山东省;新的;药品不良反应;报告分析;用药安全

        Analysis of 8 566 New ADR Reports in Shandong Province
                                                 3
                     1
                                  2
        LIU Baosheng ,ZHOU Xiuli ,GONG Kaikai (1. Dept. of Clinical Pharmacy,Weifang Hospital of TCM,
        Shandong Weifang 261000, China; 2. Dept. of Pharmacy, Sunshine Union Hospital, Shandong Weifang
        261000, China; 3. Cancer Research Laboratory, the Affiliated Hospital of Binzhou Medical University,
        Shandong Binzhou 256603,China)
        ABSTRACT   OBJECTIVE:To investigate the occurrence and characteristics of new adverse drug reactions(ADR)in Shandong
        province,so as to provide reference for the safety of drug use in the clinic. METHODS:The data of new ADR reports were collected
        from Spontaneous Reporting System of Shandong ADR Monitoring Center during Oct. 2019 to Mar. 2020. Those reports were analyzed
        statistically in respects of report types,reporting institution,reporters’occupation,gender and age of patients,drug type,organs/
        systems involved,clinical manifestations. RESULTS & CONCLUSIONS:A total of 8 566 new ADR reports were screened out,
        accounting for 10.81% of the effective ADRs. Among them,there were 7 961 new and general ADR(92.94%)and 605 new and
        serious ADRs(7.06%). For the new ADR,the reporting institutions were mainly medical institutions(98.42%),and the reporters’
        occupation were mainly doctors(78.44%). Female(4 860 cases)was slightly more than male(3 698 cases);most of them were 45
        years old and above(70.00%),and intravenous drip(47.67%)was the main route of administration. The top five ADR suspected
        drugs were TCM preparations(34.50%),anti-microbials(13.75%),circulatory system drugs(11.41%),nervous system drugs
       (6.39%)and blood system drugs(4.81%),involving 517,91,64,53,50 types,respectively,among which Levofloxacin injection
        caused the most serious ADR(24 cases). The new and general ADR mainly involved gastrointestinal system,skin and its appendant;
        their clinical manifestations were nausea,vomiting,rash,etc. New and serious ADR mainly caused systemic damage;their clinical
        manifestations were anaphylactic shock,chest tightness and shivering,etc. It is suggested to strengthen the ADR monitoring of TCM
        preparations,anti-microbials,circulatory system drugs and other drugs,so as to ensure the safety of clinical drug use.
        KEYWORDS    Shandong province;New;Adverse drug reactions;Report analysis;Safety of drug use


            药品不良反应(ADR)监测工作是药品上市后安全                        险。根据国家药品监督管理局发布的数据显示,我国
        监管的重要支撑,其目的是及时发现、控制药品安全风                           ADR 上报数量从 1999 年至 2019 年呈逐年上升趋势,其
                                                           中新的和严重的ADR一直是ADR监测评价工作的重点
           Δ 基金项目:国家自然科学基金资助项目(No.81903537)
                                                                [1]
                                                           内容 。为了解山东省新的ADR发生的现状及特点,笔
           *主管药师,硕士。研究方向:临床药学。电话:0536-8190023。
                                                           者对2019年10月-2020年3月上报至山东省ADR监测
        E-mail:1057080284@qq.com
            # 通信作者:主管药师,硕士。研究方向:临床药学。电话:                   中心自发呈报系统的新的ADR报告进行数据汇总和分
        0536-6960663。E-mail:xiulizhou1990@163.com          析,旨在为保障患者用药安全提供参考。

        中国药房    2021年第32卷第4期                                               China Pharmacy 2021 Vol. 32 No. 4  ·475 ·
   96   97   98   99   100   101   102   103   104   105   106